As Director, US Market Access Strategy, Anti-Infectives, I lead the development and execution of comprehensive strategies that ensure patient access while driving commercial success. I collaborate cross-functionally to align Pricing, Patient Services, Distribution, Payer Contracting and Brand initiatives, ensuring seamless execution across the organization.Strategic Leadership & ExecutionI design and implement market access strategies that align with commercial objectives, balancing pricing, reimbursement, and value-based healthcare to optimize product uptake and profitability.Cross-Functional Project ManagementLeading teams across key functions, I ensure integrated, efficient execution of market access initiatives, driving results through strong collaboration.Market Analysis & Competitive InsightsI conduct in-depth market and competitor analysis to identify growth opportunities, refining strategies to stay ahead of market shifts.Payer & Channel Strategy DevelopmentI work closely with payer and channel teams to drive successful negotiations, ensuring optimal patient access and reimbursement outcomes.Stakeholder EngagementI build and maintain strong relationships with internal and external stakeholders to advance market access goals and ensure effective strategy implementation.

Leading a team of District Managers & Oncology Specialists with a focus on Accountability, Collaboration, Empowerment & Execution. We represent patients & families impacted by Prostate, Lung & Bladder Cancer across 15 states & Washington, D.C.

Leading a team collaborating with Health Systems & community based Pulmonologists, Allergists & ENTs. We're focused on patients impacted by eosinophilic driven diseases that could benefit from an injectable biologic. Highlights:National Field Access Leadership liaison collaborating with Payer Marketing, Access & Training teams. Identify & increase subject matter expertise within Payer landscape. Completed 2019 110% to goal driven by 4Q2019 at 208% to goal

Leading a team launching a biologic injectable for high cholesterol and impacting the lives of Type 2 Diabetics not at goal on oral medications or basal insulin. Sales highlights:2017 - Ranked in the top 10% for portfolio performance September 2017 YTD by emphasizing population health management & distinctive patient profiles resulting in 30% increase YOY sales. 2016 - Nationally ranked in the top 18% for Praluent PCP TRx Volume December 2016 YTD due to a laser focus on the reimbursable patient & Utilization Management criteria for PCSK9i.

Promoted to reengineer a Multichannel Marketing campaign delivering clinical, organizational and financial solutions impacting patient outcomes to “low/no-access” C-Suite personnel and Administrators within IDNs, Medical Groups and Long Term Care facilities. Highlights:2015 - Increased click rates and call to action of requests for new product information via dedicated HCP product website. 2014 - Upgraded Medicare Part D Benchmark Payer Resource Guide resulting in 42% increase in Account Manager interaction with key stakeholders and 27% in YOY sales.

Coached First and Second Line Leaders on how to accurately rate Hospital and Health Systems Account Managers sales competencies (business acumen, scientific knowledge & selling skills) in a National HR driven project. Highlights:2013 - Reduction in unconscious bias and micro inequities for Leaders participating in the program. 2012 - Created District Manager simulation presenting an accurate depiction of issues impacting healthcare providers, therefore improving subsequent training modules to meet customer needs.

Promoted to lead a team of Account Managers and Sales Representatives implementing population health projects with C-Suite personnel, Administrators and HCPs in Corporate Medical Groups. Sales Highlights:2012 - Implemented 3 COPD projects impacting ~9k patients reducing hospital admissions due to exacerbations. - Improved Advair sales by 94%2011 - Initiated an Asthma project impacting ~25k patients by reducing sick visits and albuterol overuse. - Enhanced Ventolin sales by 52%. - Increased Flovent sales by 32%

Led a team of Change Agents utilizing Continuous Improvement skill-sets to initiate lean Six Sigma projects to impact employee engagement and accountability while reducing waste. Highlights:2010 - Increased Business Unit engagement scores by 9-24 points on 6 key areas of Change Management and Transparency - Resulted in $3M incremental YOY sales.

Promoted to lead multiple teams to uncover HCPs goals, how they’re measured, what’s getting in the way and present solutions in the Cardio-Metabolic, Pediatric, Respiratory, Urology, Rheumatology, Dermatology and Anti-viral space. Sales Highlights:2009 - Nationally ranked in the top 9% due to a hyper focus on understanding HCP and patient issues, then aligning appropriate resources. - Winner’s Circle2007 - Increased district sales by 21% vs. national average of 4% for teams participating in a pilot alternative selling model.

Implemented an under-utilized resource (12 week call plan) to consistently engage high prescribing HCPs to understand their goals, how they’re measured and what’s getting in the way. Sales Highlights:2006 - Nationally ranked in the top 5% of 585 representatives and won Winner’s Circle2004 - Nationally ranked in the top 4% of 585 representatives and won Winner’s Circle